Pain and Problem Behavior in Cats and Dogs.

We argue that there is currently an under-reporting of the ways in which pain can be associated with problem behavior, which is seriously limiting the recognition of this welfare problem. A review of the caseloads of 100 recent dog cases of several authors indicates that a conservative estimate of around a third of referred cases involve some form of painful condition, and in some instances, the figure may be nearly 80%. The relationship is often complex but always logical. Musculoskeletal but also painful gastro-intestinal and dermatological conditions are commonly recognized as significant to the animal's problem behavior. The potential importance of clinical abnormalities such as an unusual gait or unexplained behavioral signs should not be dismissed by clinicians in general practice, even when they are common within a given breed. In general, it is argued that clinicians should err on the side of caution when there is a suspicion that a patient could be in pain by carefully evaluating the patient's response to trial analgesia, even if a specific physical lesion has not been identified.

Tools for Managing Feline Problem Behaviours Psychoactive medications.

PRACTICAL RELEVANCE: When a cat is presented for evaluation of a problem behaviour, it is likely that the cat's wellbeing is negatively affected by the condition. In addition, the owners and any other animals around the cat may also be experiencing negative consequences. When managing these cases, it is important to consider all options (including behaviour modification, environmental changes, medications) that can help to reach an optimal solution. Medication cannot teach the cat how to behave or change a particular behaviour; it can, however, reduce arousal, excitability, reactivity and anxiety. RATIONALE: The rationale for using psychoactive medications in behavioural medicine, or veterinary psychiatry, is to increase the wellbeing of the animal and to aid the owner and practitioner in managing problem behaviours. Medications should always be used as an adjunct to behavioural and environmental modification. CLINICAL CHALLENGES: Many psychoactive medications cannot be used in the face of certain physical illnesses or concurrently with other medications. Some medications may also have side effects, not be effective at the recommended dose or have a paradoxical effect. Furthermore, success is reliant on the owner being able to administer the medication. AIMS: This article aims to guide practitioners by discussing questions such as how to choose the appropriate medication, how to dose it and how long to use it. The psychoactive medications most commonly used in feline medicine are reviewed, as well as some that are newer or less common. EVIDENCE BASE: Data for the use of medications in cats is limited, with just a small number of clinical-, species- and problem-directed studies available, and a few more case series and case reports. Where feline-specific research is not available, the authors have drawn upon research published in other species, such as humans, dogs and rats, as well as anecdotal reports and expert opinions.

Cognitive dysfunction in cats: a syndrome we used to dismiss as 'old age'.

PRACTICAL RELEVANCE: Cognitive dysfunction syndrome (CDS) is a widely accepted diagnosis in dogs, with established treatment options. In cats, however, our understanding of cognitive dysfunction is still being shaped by ongoing research in the field, and limited treatment options are available. Recent clinical studies indicate that old age in the cat is accompanied by increased behavioural signs such as wandering, vocalization and night-time activity that are not attributable to identifiable medical problems. It is essential, therefore, that veterinarians include behavioural well-being in the routine care of senior cats. PATIENT GROUP: While the exact age of onset is not established, studies suggest that age-related behavioural changes consistent with cognitive dysfunction are prevalent in cats as early as 10 years of age and that prevalence increases significantly in older cats. CLINICAL CHALLENGES: The diagnosis of cognitive dysfunction requires the identification of geriatric behavioural changes that are not caused by other medical problems, although the two may not be mutually exclusive. Therefore, the practitioner must rely heavily on owner reports and history to ensure prompt diagnosis and treatment. The absence of any approved dietary or pharmaceutical interventions for cognitive dysfunction adds a further challenge, although several possibilities exist. EVIDENCE BASE: This article draws on recent research that has produced neuropathological, cognitive and behavioural evidence for cognitive dysfunction in aging cats. As an impetus to further our understanding of this disease and potential treatment options, the authors propose a behavioural checklist that might aid in the clinical diagnosis of feline CDS and discuss treatment options that have proven successful in the canine counterpart of this disease.

Effects of dog-appeasing pheromones on anxiety and fear in puppies during training and on long-term socialization.

OBJECTIVE: To evaluate the effectiveness of dog-appeasing pheromone (DAP) in reducing fear and anxiety in puppies and its effects on training and socialization. DESIGN: Randomized, controlled clinical trial. ANIMALS-45 puppies between 12 to 15 weeks of age at the time of inclusion. PROCEDURES: Puppies enrolled in puppy classes were randomly allocated to 1 of 4 groups: 2 large-breed groups (1 DAP and 1 placebo group) and 2 small-breed groups (1 DAP and 1 placebo group). The investigator, trainers, and owners were unaware of treatment allocation throughout the study. Classes lasted 8 weeks, and owners were asked to complete a questionnaire before the first lesson and at the end of each lesson thereafter. Data collected included amount of learning and degrees of fear and anxiety for each puppy. Follow-up telephone surveys of owners to obtain information on subsequent socialization of puppies were performed at 1, 3, 6, and 12 months after the classes ended. RESULTS: Dogs in DAP and placebo groups were significantly different with respect to degrees of fear and anxiety; longer and more positive interactions between puppies, including play, were evident in dogs in the DAP groups. Data from follow-up telephone surveys indicated that puppies in the DAP groups were better socialized and adapted faster in new situations and environments, compared with puppies in the placebo groups. CONCLUSIONS AND CLINICAL RELEVANCE: When compared with a placebo treatment, DAP was useful in reducing anxiety and fear in puppies during puppy classes and resulted in improved socialization.